Literature DB >> 20735441

Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barré syndrome?

I Steiner1, G Rosenberg, I Wirguin.   

Abstract

Guillain-Barré syndrome (GBS) is an acute, usually monophasic, disorder of the peripheral nervous system that is assumed to be of immune-mediated pathogenesis. However, several clinical features and experimental findings of GBS are uncharacteristic for an immune-mediated disorder and set this condition apart from other disorders with a putative immune-mediated pathogenesis. These features include, among others, the monophasic nature of GBS, the lack of response to immunosuppressive (unlike immunomodulatory) therapy, the absence of a typical association with immunogenetic background and the inability to establish a valid and relevant animal model. We suggest a comprehensive hypothesis for the pathogenesis of GBS that is based on the assumption that the condition is due to a transient (or occasionally chronic) immune deficiency, as in most cases GBS follows an infection with pathogens known to induce immunosuppression. Such infections may be followed by breakdown of immune tolerance and induction of an immune attack on peripheral nerves. Mounting of the immune-mediated assault might be triggered either by the same infective pathogen or by secondary infection. Clearance of the infection and resumption of a normal immune response and tolerance eventually terminate the immune-mediated damage to the peripheral nerves and enable recovery. This hypothesis assumes that the entire sequence of events that culminates in GBS is due to transient exogenous factors and excludes a significant role for inherent host susceptibility, which explains the monophasic nature of the disorder.
© 2010 The Authors. Clinical and Experimental Immunology © 2010 British Society for Immunology.

Entities:  

Mesh:

Year:  2010        PMID: 20735441      PMCID: PMC2990927          DOI: 10.1111/j.1365-2249.2010.04223.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  98 in total

Review 1.  Genetic progress towards the molecular basis of autoimmunity.

Authors:  Simon H S Pearce; Tony R Merriman
Journal:  Trends Mol Med       Date:  2006-01-18       Impact factor: 11.951

Review 2.  T-cell and macrophage activation in experimental autoimmune neuritis and Guillain-Barré syndrome.

Authors:  H P Hartung; K V Toyka
Journal:  Ann Neurol       Date:  1990       Impact factor: 10.422

3.  Differential distribution of HLA-DQ beta/DR beta epitopes in the two forms of Guillain-Barré syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ beta epitopes associated with susceptibility to and protection from AIDP.

Authors:  Eleni E Magira; Miltiadis Papaioakim; Irving Nachamkin; Arthur K Asbury; Chun Y Li; Tony W Ho; John W Griffin; Guy M McKhann; Dimitri S Monos
Journal:  J Immunol       Date:  2003-03-15       Impact factor: 5.422

Review 4.  The immunobiology of Guillain-Barré syndromes.

Authors:  Hugh J Willison
Journal:  J Peripher Nerv Syst       Date:  2005-06       Impact factor: 3.494

5.  Family with inflammatory demyelinating polyneuropathy and the HNPP 17p12 deletion.

Authors:  Isabelle Korn-Lubetzki; Zohar Argov; Annick Raas-Rothschild; Itzchak Wirguin; Israel Steiner
Journal:  Am J Med Genet       Date:  2002-12-01

6.  Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus.

Authors:  Tal I Arnon; Hagit Achdout; Ofer Levi; Gal Markel; Nivin Saleh; Gil Katz; Roi Gazit; Tsufit Gonen-Gross; Jacob Hanna; Efrat Nahari; Angel Porgador; Alik Honigman; Bodo Plachter; Dror Mevorach; Dana G Wolf; Ofer Mandelboim
Journal:  Nat Immunol       Date:  2005-04-10       Impact factor: 25.606

7.  Campylobacter Enteritis and the Guillain-Barré Syndrome.

Authors:  Irving Nachamkin
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

8.  Acute inflammatory demyelinating polyneuropathy following bone marrow transplantation.

Authors:  S Eliashiv; T Brenner; O Abramsky; R Shahin; E Agai; E Naparstek; I Steiner
Journal:  Bone Marrow Transplant       Date:  1991-10       Impact factor: 5.483

9.  The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines.

Authors:  T Lasky; G J Terracciano; L Magder; C L Koski; M Ballesteros; D Nash; S Clark; P Haber; P D Stolley; L B Schonberger; R T Chen
Journal:  N Engl J Med       Date:  1998-12-17       Impact factor: 91.245

Review 10.  Fisher syndrome and Bickerstaff brainstem encephalitis (Fisher-Bickerstaff syndrome).

Authors:  Nobuhiro Yuki
Journal:  J Neuroimmunol       Date:  2009-07-29       Impact factor: 3.478

View more
  6 in total

1.  Broadening the translational immunology landscape.

Authors:  M Peakman
Journal:  Clin Exp Immunol       Date:  2012-12       Impact factor: 4.330

Review 2.  Revisiting the old link between infection and autoimmune disease with commensals and T helper 17 cells.

Authors:  J Magarian Blander; Miriam B Torchinsky; Laura Campisi
Journal:  Immunol Res       Date:  2012-12       Impact factor: 2.829

3.  Guillain-Barré syndrome and severe infection following chemotherapy for peripheral T-cell lymphoma: A case report.

Authors:  Yang-Yang Ma; Lei Zhang; DA-Liang Zhang; Wen-Shuo Liu
Journal:  Oncol Lett       Date:  2014-09-16       Impact factor: 2.967

4.  The clinical characteristics and short-term prognosis in elderly patients with Guillain-Barré syndrome.

Authors:  Bing Zhang; Xiujuan Wu; Donghui Shen; Ting Li; Chunrong Li; Mei Mao; Hong-Liang Zhang; Kangding Liu
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

5.  Are Cerebrospinal Fluid Protein Levels and Plasma Neutrophil/Lymphocyte Ratio Associated with Prognosis of Guillain Barré Syndrome?

Authors:  Sevki Sahin; Nilgun Cinar; Sibel Karsidag
Journal:  Neurol Int       Date:  2017-06-23

6.  Probiotics as a Potential Alternative for Relieving Peripheral Neuropathies: a Case for Guillain-Barré Syndrome.

Authors:  Abhishek Saxena
Journal:  Front Microbiol       Date:  2016-01-07       Impact factor: 5.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.